MediPharm Labs Corp. has entered the European healthcare cannabis marketplace following it signed its initial private label sales agreement with German pharmaceutical and healthcare cannabis distributor ADREXpharma GmbH. MediPharm noted that it is the initial extraction-only organization with a provide agreement for export to Germany.
By way of its private label options platform, Canada-primarily based MediPharm Labs will provide ADREXpharma with cannabis concentrate derivative solutions that will be sold and distributed below the ADREXpharma brand in Germany upon receipt of applicable regulatory approvals. The cannabis concentrate derivative solutions involve THC and CBD oil.
ADREXpharma is an independent German pharmaceutical organization specialized in the improvement and distribution of medicinal cannabis in the European marketplace. The organization has created a number of dosages such as extracts, powder, resin, and flowers for the increasing pharma marketplace in Germany.
ADREXpharma can serve all of the approximate 20,000 pharmacies in Germany by way of its provide network, MediPharm Labs noted.
“Germany is 1 of the biggest and quickest increasing healthcare cannabis markets in the planet and represents MediPharm Labs’ second big international milestone as we prepare to export our private label cannabis concentrates into Germany,” stated Pat McCutcheon, CEO of MediPharm Labs.
According to a Bank of Montreal report in August 2019, the quantity of German healthcare cannabis individuals has elevated to an estimated 30,000 to 50,000 individuals from 1,000 given that legalization in 2017, with the individuals paying greater typical costs than in Canada.
A report published by the Bank of Montreal in November 2018 estimated the European Union healthcare cannabis marketplace size could attain $30 billion by 2026.
In early September, MediPharm Labs stated its subsidiary MediPharm Labs Australia Pty. Ltd. entered into a private label sales and manufacturing agreement with a licensed cannabis producer in Australia.
Below the terms of the manufacturing agreement, MediPharm Labs Australia will obtain dried flower from the licensed producer and sell private-label cannabis oil and manufactured solutions in Australia. The agreement has a twelve-month term with alternatives to extend.
For comments and feedback speak to: [email protected]
Small business News